Advanced searches left 3/3

Metastatic Cancer Gemcitabine - Europe PMC

Summarized by Plex Scholar
Last Updated: 03 May 2022

* If you want to update the article please login/register

Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.

Background Pancreatic cancer is a risk factor that can cause significant thromboembolism. With gemcitabine plus paclitaxel, we investigated the significance of early venous thromboembolism detection in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel. Methods This single-center retrospective analysis enrolled 174 patients with UR-MPC who underwent GnP as a first-line chemotherapy from April 2017 to March 2020 in this single-center retrospective study. At diagnosis, thirteen patients were diagnosed with VTE at diagnosis, and four patients were hospitalized after treatment began. The VTE group had worse OS and PFS than the VTE group, which was worse. In multivariate studies, although the results in the VTE group was poorer, VTE was identified as a statistically significant independent predictor of OS. Resulting in Early VTE testing for patients with UR-MPC patients who receive GnP as first-line chemotherapy, even if patients are symptomatic.

Source link: https://europepmc.org/article/MED/35231078


Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study.

Background facts regarding long-term success in gemcitabine-concurrent proton radiotherapy for non-metastatic, locally advanced pancreatic cancer are uncertain. Methods The medical records of 123 patients with LAPC treated with GPT between February 2009 and December 2019 at Hyogo Ion Beam Medical Center were retrospectively reviewed to determine the risk factors associated with long-term survival outcomes. Patients with LAPC with anterior peripancreatic invasion and those with LAPC without anterior peripancreatic invasion were 24. 1 and 28. 1 months, respectively. The pancreatic body-tail had a higher volume ratio of gross tumor volume at 60 Gy compared to those at the pancreatic head, which was higher. Earlier peripancreatic invasion LAPCs with anterior peripancreatic invasion had more peritoneal recurrence within 6 months after GTP than those without anterior peripancreatic invasion. GPT is a promising treatment option for patients with LAPC in the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion.

Source link: https://europepmc.org/article/MED/35144647

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions